Core Viewpoint - The animal health sector experienced a rise of 0.93% on January 16, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4101.91, down 0.26% [1]. - The Shenzhen Component Index closed at 14281.08, down 0.18% [1]. Group 2: Individual Stock Performance - BioShares (600201) led the gains with a closing price of 17.61, up 3.53%, and a trading volume of 480,000 shares, amounting to a transaction value of 840 million yuan [1]. - Other notable performers included: - Huisheng Bio (300871) at 26.03, up 1.36%, with a transaction value of 434 million yuan [1]. - Xianfeng Holdings (002141) at 3.76, up 1.35%, with a transaction value of 8.13 million yuan [1]. - Ruipu Bio (300119) at 20.15, up 0.90%, with a transaction value of 110 million yuan [1]. - Shunlian Bio (688098) at 9.60, up 0.63%, with a transaction value of 40.84 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 112 million yuan from institutional investors, while retail investors experienced a net outflow of 68.65 million yuan [2]. - The capital flow for individual stocks showed: - BioShares had a net inflow of 75.95 million yuan from institutional investors [3]. - Huisheng Bio had a net inflow of 19.63 million yuan from institutional investors [3]. - Xianfeng Holdings had a net inflow of 16.40 million yuan from institutional investors [3].

Group 1 - The core viewpoint of the news is that Haili Biological experienced a decline in stock price and trading volume, with significant details on financing and stockholder changes [1][2] Group 2 - On January 15, Haili Biological's stock fell by 1.83%, with a trading volume of 83.6 million yuan [1] - The financing data shows that on the same day, Haili Biological had a financing purchase amount of 9.52 million yuan, with a net financing purchase of 2.78 million yuan [1] - As of January 15, the total balance of margin trading for Haili Biological was 212 million yuan, with the financing balance accounting for 5.06% of the circulating market value, indicating a low level compared to the past year [1] - In terms of securities lending, Haili Biological had a securities lending repayment of 1,300 shares and a securities lending sell of 2,000 shares, with a total lending balance of 44.05 million yuan, also at a low level compared to the past year [1] Group 3 - As of September 30, the number of shareholders for Haili Biological increased to 33,800, a rise of 7.16%, while the average circulating shares per person decreased by 6.68% [2] - For the period from January to September 2025, Haili Biological reported a revenue of 150 million yuan, a year-on-year decrease of 14.15%, while the net profit attributable to the parent company was 20.33 million yuan, reflecting a slight increase of 0.77% [2] - Haili Biological has distributed a total of 209 million yuan in dividends since its A-share listing, with 107 million yuan distributed over the past three years [2] - Among the top ten circulating shareholders as of September 30, 2025, Guotai Zhongzheng Livestock Breeding ETF ranked as the fifth largest shareholder, increasing its holdings by 3.70 million shares to 10.23 million shares [2]

Core Viewpoint - The acquisition of Rui Sheng Biological by Haili Biological has led to unexpected valuation declines and questionable client relationships, raising concerns about financial transparency and potential misrepresentation in disclosures [1][3][5]. Group 1: Acquisition and Valuation - Haili Biological acquired 55% of Rui Sheng Biological for 935 million yuan, valuing the company at 1.711 billion yuan, representing a 952% increase in book value [1]. - Rui Sheng Biological's valuation was subsequently revised down to 974 million yuan, reflecting a 43% drop within eight months post-acquisition due to declining performance [1][2]. Group 2: Client Relationships and Disclosures - Wuhan He Mu Medical Technology, registered in April 2023, was listed as Rui Sheng Biological's largest client for 2022, raising questions about the legitimacy of this relationship [3][4]. - The explanation provided by Haili Biological regarding the client relationship was deemed insufficient by financial experts, suggesting potential financial misrepresentation [5][6]. - A second client, Shandong Quanming Medical, initially listed as a major client, later denied any collaboration with Rui Sheng Biological, further complicating the company's client disclosure credibility [9][10][11]. Group 3: Industry Context and Performance - Rui Sheng Biological's products, particularly in the dental implant repair materials sector, had previously seen rapid growth due to favorable market conditions and increased demand post-COVID-19 [22][23]. - However, the company faced significant challenges in 2025, including a 50%-60% price drop in bone powder products and increased competition, leading to a substantial decline in revenue and profit [23][24].

Market Overview - The animal health sector experienced a decline of 0.44% on January 14, with Haili Biological leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.39, up 10.65% on a trading volume of 112,300 shares and a turnover of 118 million yuan [1] - Huisheng Biological (code: 300871) closed at 25.52, up 1.84% with a trading volume of 270,100 shares and a turnover of 696 million yuan [1] - Major decliners included: - Haili Biological (code: 603718) closed at 6.55, down 1.65% with a trading volume of 237,400 shares and a turnover of 157 million yuan [2] - Zhongmu Co., Ltd. (code: 600195) closed at 7.92, down 1.61% with a trading volume of 201,400 shares and a turnover of 161 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 140 million yuan from institutional investors, while retail investors experienced a net inflow of 52.14 million yuan [2] - The detailed capital flow for selected stocks showed: - Huisheng Biological had a net inflow of 23.06 million yuan from institutional investors [3] - ST Green Kang (code: 002868) faced a significant net outflow of 5.87 million yuan from institutional investors [3]

Core Insights - The acquisition of Rui Sheng Biological by Haili Biological has led to unexpected valuation adjustments, with Rui Sheng's valuation dropping from 1.7 billion RMB to 974 million RMB due to performance declines [7][18] - The presence of a company that was not yet established as a major client of Rui Sheng raises questions about the accuracy of financial disclosures [9][11] - The investigation revealed inconsistencies in client relationships and potential issues with financial reporting practices [20][21] Group 1 - Haili Biological acquired 55% of Rui Sheng Biological for 935 million RMB, resulting in a valuation increase of 952% at the time of acquisition [7] - Rui Sheng Biological's valuation was subsequently revised downwards due to declining performance, with a projected valuation of 974 million RMB by June 2025 [7][18] - The company claims to be a leading player in the market for natural calcined bone repair materials, particularly in dental applications [7] Group 2 - Wuhan He Mu Medical Technology, a client listed by Rui Sheng, was found to have been established only in April 2023, raising questions about its status as a major client [10][11] - The explanation provided by Haili Biological regarding the client relationship was deemed insufficient by financial experts, suggesting potential financial misrepresentation [11][18] - The investigation into client relationships revealed that actual business dealings may have been misrepresented, with claims of shared operations between different entities [13][15] Group 3 - The performance of Rui Sheng Biological has been adversely affected by increased competition and price wars, leading to a significant drop in revenue and profit margins [42][43] - The company reported a revenue of 26.77 million RMB and a net profit of 9.29 million RMB in Q3 2025, indicating a substantial decline compared to previous quarters [42] - Haili Biological plans to expand its operations by acquiring stakes in dental chain companies, which is expected to positively impact its financial performance in 2026 [43][44]

每经成都1月13日电海利生物（603718.SH）并购的"隐形冠军"陕西瑞盛生物科技有限公司（以下简称瑞 盛生物），在交易完成仅八个月后，估值即从17亿元骤降至9.74亿元。 （文章来源：每日经济新闻） 每经记者调查发现，海利生物披露的瑞盛生物2022年第一大客户"武汉合木"，却是于2023年4月才成 立，出现了"未成立即成为大客户"的时间悖论。对此，瑞盛生物解释系将前后合作方"合并披露"，但财 务专家指出，这如同"提前一年为未出生的孩子报户口"。 此外，另一大客户山东泉名的法定代表人对同瑞盛生物的交易金额及细节一问三不知，与海利生物公告 中描述的山东泉名实控人"主动寻求代理"存在明显矛盾。 ...

Core Viewpoint - The acquisition of Rui Sheng Biological by Haili Biological, which was expected to enhance performance, has instead led to a significant valuation drop and questionable client disclosures, raising concerns about potential financial misrepresentation [2][6][7]. Group 1: Acquisition and Valuation - Haili Biological acquired 55% of Rui Sheng Biological for 935 million RMB, valuing the company at 1.7 billion RMB, representing a 952% increase in value [6]. - Following a performance decline, Rui Sheng Biological's valuation was revised down to 974 million RMB, nearly halving within eight months post-acquisition [6][10]. - Rui Sheng Biological is recognized as a hidden champion in Shaanxi Province, specializing in natural calcined bone repair materials [6]. Group 2: Client Disclosure Issues - A company that was registered in 2023, Wuhan Hemu, was listed as the largest client of Rui Sheng Biological for 2022, raising questions about the legitimacy of this disclosure [10][11]. - Haili Biological explained that the collaboration with Wuhan Hemu predates its official establishment, but this explanation has been challenged by financial experts [10][14]. - The actual business relationship appears to be with Wuhan Xin Hao Medical, which has a shared email address and phone number with Wuhan Hemu, suggesting potential misrepresentation [13][14]. Group 3: Customer Relationship Discrepancies - Shandong Quanming Medical, listed as a major client, denied any collaboration with Rui Sheng Biological, contradicting the company's disclosures [23][30]. - The legal representative of Shandong Quanming initially denied any partnership but later acknowledged that there had been some form of cooperation, although details were unclear [34][37]. - The discrepancies in client relationships and the nature of contracts raise concerns about the accuracy of financial reporting and potential regulatory implications [14][37]. Group 4: Industry Context and Performance - The dental implant market, particularly for bone powder, has seen significant demand due to post-COVID recovery and government policies promoting dental care [43][45]. - Rui Sheng Biological's revenue growth from 2021 to 2023 was reported at a compound annual growth rate of 84.59%, attributed to market conditions and product advantages [45]. - However, in 2025, the company faced a sharp decline in revenue and profit due to increased competition and price wars, with bone powder prices dropping by 50% to 60% [45].

Group 1 - The acquisition of Ruisheng Bio by Haili Bio has resulted in a significant valuation drop, with the company's estimated value reduced from 1.7 billion yuan to 974 million yuan due to performance decline [5][39] - Ruisheng Bio, identified as a "hidden champion" in Shaanxi Province, specializes in natural calcined bone repair materials and has established a leading market position in dental implant repair materials [5][39] - The financial performance of Ruisheng Bio has been questioned, particularly regarding its customer relationships, with a newly established company appearing as a major client before its official registration [6][9] Group 2 - Haili Bio acquired 55% of Ruisheng Bio for 935 million yuan, reflecting a 952% increase in value since the initial purchase of multiple companies, including Ruisheng Bio, for 35 million HKD [5][39] - The sales figures for Ruisheng Bio's major clients in 2022 and 2023 show discrepancies, with a significant portion of sales attributed to clients that were either newly established or claimed to have no prior relationship with Ruisheng Bio [8][20] - The investigation revealed that the actual business relationships and sales figures may not align with the disclosures made by Ruisheng Bio, raising concerns about potential financial misrepresentation [12][13] Group 3 - The competitive landscape in the dental implant market has intensified, leading to a drastic price drop of 50% to 60% for bone powder products, which has adversely affected Ruisheng Bio's revenue [38] - Despite a compound annual growth rate of 84.59% in revenue from 2021 to 2023, Ruisheng Bio reported a significant decline in revenue and profit in the third quarter of 2025 [37][38] - Haili Bio plans to expand its business by acquiring stakes in dental chain companies, which is expected to positively impact its revenue and profit in 2026 [39]

Core Insights - The animal health sector experienced a rise of 1.09% on January 13, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Huisheng Biological (300871) closed at 25.06, up 8.39%, with a trading volume of 276,700 shares and a transaction value of 700 million [1] - Other notable performers included: - Qudongli (920275) at 65.6, up 3.99% [1] - Haili Biological (603718) at 6.66, up 1.99% [1] - Xianfeng Holdings (002141) at 3.77, up 1.34% [1] - Shunlian Biological (688098) at 9.78, up 1.03% [1] Capital Flow - The animal health sector saw a net inflow of 34.99 million from institutional investors, while retail investors contributed a net inflow of 30.94 million [2] - However, speculative funds experienced a net outflow of 65.94 million [2] Individual Stock Capital Flow - Major net inflows were observed in: - Biological Shares (600201) with a net inflow of 39.54 million [3] - Jinhe Biological (002688) with a net inflow of 13.45 million [3] - Xianfeng Holdings (002141) with a net inflow of 10.20 million [3] - Conversely, significant net outflows were noted in: - Biological Shares (600201) with a net outflow of 48.25 million from speculative funds [3] - Jinhe Biological (002688) with a net outflow of 1.46 million from retail investors [3]

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]